CA
ZYNE

Cornerstone Advisory’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cornerstone Advisory’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed – – 845
2021
Q4 		$0 Buy
+25
New +$92 ﹤0.01% 863

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cornerstone Advisory's ZYNE Position: Q1 2022 in Review

Cornerstone Advisory sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 25 shares.

Cornerstone Advisory first reported a position in ZYNE in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • Cornerstone Advisory reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • Cornerstone Advisory sold 25 Zynerba Pharmaceuticals, Inc shares in Q1 2022.
  • Cornerstone Advisory first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and held it in 1 quarter.
  • Cornerstone Advisory's Zynerba Pharmaceuticals, Inc position peaked at $0 in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.